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Two suppression subtracted cDNA libraries have been constructed, one containing cDNAs to mRNAs present at a higher
level in a benign human breast tumour-derived cell line relative to the malignant mammary cell line, MCF-7, and the other
containing cDNAs present at a higher level in the MCF-7 cells relative to the benign cells. Randomly-picked cloned DNAs
have been sequenced yielding 29 and 128 different cDNAs from the benign and malignant libraries, respectively. Using reverse
Northern hybridisation, 76% and 83% of the cDNAs were differentially expressed by greater than two-fold, whilst 14% and
11% of cDNAs in the respective libraries were differentially expressed by more than 15-fold. Amongst these were oestrogen-
responsive cDNAs and expressed sequence tags. One such oestrogen-responsive expressed sequence tag, M41, is transcribed
from a gene located on chromosome 21q22.3, within an intron of a larger gene. The M41 gene contains oestrogen response
elements, one of which is associated with alu repeats. M41 mRNA is expressed at a statistically signiﬁcantly higher level in
human breast cancer specimens than in normal human breast and benign lesions. In carcinomas, its up-regulation is associated
with the development of the malignant cell.
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Cancer in the Western world affects one in three of the population,
and it is the malignant properties of invasion and metastasis that
are harmful to the patient. Many cancers are thought to arise from
tumours, which progress from a benign state to a malignant one
(Nowell, 1986). The benign tumours can arise by a variety of
mechanisms including changes in gene expression and mutation
of key growth regulatory genes; however, the progression of a
tumour to a life-threatening malignant state involves more-wide-
spread changes in gene expression (Fearon and Vogelstein, 1990).
Thus, the difference between the behaviour of benign tumour cells
and cancer cells is likely to be explained, at least in part, by iden-
tifying the genes and gene products which are differentially
expressed between them (Martin et al, 2000). Such an approach
has yielded the metastasis-inducing protein S100A4 (Davies et al,
1993; Barraclough, 1998). In order to identify a wider range of
mRNAs encoding protein products which might contribute to
the progression of oestrogen receptor positive breast tumour cells,
PCR -selected suppression subtractive hybridisation has now been
employed to construct subtracted libraries in alternative orienta-
tions using mRNAs isolated from a benign human mammary
epithelial cell line, Huma 123 (Ke et al, 1993), and from the malig-
nant human mammary epithelial cell line, MCF-7. The resulting
subtracted libraries not only contain previously-characterised
differentially-expressed cDNAs associated with the presence of
oestrogen receptor, but also contain novel cloned cDNAs which
may also be associated with the development of breast cancer.
MATERIALS AND METHODS
Human breast cell lines
Huma 7, a normal human mammary epithelial cell line that had
been immortalised with SV40 virus (Rudland et al, 1989), Huma
123, a benign human mammary epithelial cell line, and Huma
109, a benign human mammary elongated myoepithelial-like cell
line, derived from a primary cell culture of human ﬁbrocystic
disease displaying prominent epithelial hyperplasia (Briand et al,
1987; Ke et al, 1993), and the malignant human mammary epithe-
lial cell lines, MCF-7, T47D, and ZR-75-1, derived from pleural
effusions of breast cancer patients (Soule et al, 1973; Engel and
Young, 1978) and MDA-MB-231 (Cailleau et al, 1974) were propa-
gated in a humidiﬁed atmosphere of 95% air, 5% CO2 at 378Ca s
described below. The Huma 7 cell line was grown in DMEM, 5%
(v v
71) foetal calf serum (FCS), 50 ng ml
71 each of insulin and
hydrocortisone. The benign cell lines were grown in 50% DMEM,
50% RPMI 1640 medium, 5% (v v
71) FCS, 50 ng ml
71 insulin,
5n gm l
71 EGF (Rudland et al, 1989; Ke et al, 1993). Cell line
MCF-7 was propagated in DMEM, 5% (v v
71) FCS, 50 ng ml
71
insulin, 10
78 M oestradiol; T47D in DMEM, 10% (v v
71) FCS,
1 mgm l
71 insulin, 2.5 ng ml
71 EGF; ZR-75-1 in DMEM, 5%
(v v
71) FCS, 2.5 ng ml
71 EGF, 10
78 M oestradiol. The MDA-
MB-231 cell line was propagated in DMEM, 5% (v v
71) FCS,
50 ng ml
71 insulin, 2.5 ng ml
71 EGF. Media used for growing
cells contained phenol red. Cell lines were grown in the same batch
of foetal calf serum and harvested when they reached 70% conﬂu-
ence. MDA-MB-231 cells were growing slightly faster than Huma
7, Huma 109, MCF-7, T47D, ZR-75-1, and Huma 123 were grow-
ing slightly more slowly than the others. Broadly, however, the cells
were growing at a similar rate.
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www.bjcancer.comThe Huma 123 cells, used for the construction of the subtracted
libraries, are a unique single-cell cloned line derived from a
primary culture of human benign ﬁbrocystic disease. The cell line
has been characterised as a breast epithelial cell by immunochem-
ical detection of breast epithelial-associated antigens, epithelial
membrane antigen, milk fat globule membrane antigen and keratin
18 in cell culture and in tumours produced in immunosuppressed
nu-nu mice. In culture, the cells are diploid both in culture and
when growing in tumours in nu-nu mice. They possess regular
nuclei with little or no pleomorphism, consistent with a nonmalig-
nant morphology. The tumours are encapsulated and show no
evidence of local invasion or dissemination. Huma 123 cells thus
have the characteristics of a neoplastic but not malignant pheno-
type (Ke et al, 1993; Rudland, 1993). The Huma 123 cell line
has not been manipulated in order to make it immortal for culture
purposes. Since it is difﬁcult to obtain cultures of normal/benign
human breast epithelial cells, the Huma 123 cell line is uniquely
suited for comparison with more malignant cells for studies into
the early stages of the development of malignancy.
Construction of subtracted cDNA libraries between human
breast tumour cell lines, Huma 123 and MCF-7
Suppression subtracted libraries were constructed using a PCR-
Select
TM cDNA Subtraction Kit (Clontech, Palo Alto, CA, USA),
according to the manufacturer’s methodology. Critical steps of
the construction of the libraries were checked before proceeding
to the next step. Double-stranded cDNAs of both tester and driver
were synthesised from 2 mg poly(A)
+-containing RNA derived from
the cultured benign cell line, Huma 123 and the malignant cell line
MCF-7. The efﬁciencies of double-stranded cDNA synthesis and
digestions with restriction enzyme RsaI were monitored by agarose
gel electrophoresis. The two portions of fragmented ds cDNAs of
tester, ligated with different speciﬁc adaptors (1 and 2) were
subjected to hybridisation with the fragmented ds cDNA of driver.
After suppression PCR ampliﬁcation, the resulting subtracted PCR
pools of benign or malignant subtracted libraries ranged in size
from 200 bp to 1 kbp. The PCR products constituting the
subtracted libraries were ligated into a ddT-tailed pBluescript
vector, and transformed into E. coli XL-1 blue bacteria by electro-
poration, followed by plating on agar containing ampicillin, IPTG
and X-gal. More than 90% of the randomly-picked clones
contained cDNA inserts.
DNA sequencing analysis of the subtracted libraries
Nucleic acid sequences of cDNA clones from the benign and malig-
nant subtracted libraries were determined using an automated ABI
377 DNA sequencing system and standard dye terminator Ampli-
Taq kits (Perkin Elmer, Buckinghamshire, UK). The resulting
DNA sequences were analysed for homology using the public
GenBank/EMBL/DDBJ/PDB and Expressed Sequence Tag (EST)
databases using the Basic Local Alignment Search Tool (BLAST)
program (http://www.ncbi.nlm.nih.gov/BLAST) (Altschul et al,
1990). The DNA sequences were further analysed using the GCG
program (University of Wisconsin, WI, USA).
Differential screening of the subtracted libraries using
reverse Northern blot
The cloned cDNA inserts were ampliﬁed directly from individual
colonies of both subtracted benign and malignant libraries using
colony PCR. After ampliﬁcation, PCR products were denatured
and spotted onto duplicate nylon membranes using a slot- or
dot-blot apparatus. The ﬁlters were hybridised with equal concen-
trations of double-stranded cDNA derived from driver and tester
mRNA, respectively, which had been labelled to approximately
equal speciﬁc activity (1610
9 d.p.m mg
71 DNA) with
32P-dCTP
as described previously (Feinberg and Vogelstein, 1984).
RNA electrophoresis and Northern hybridisation
Gel electrophoresis of RNA in formaldehyde denaturing gels and
Northern blotting were performed according to standard proce-
dures (Sambrook et al, 1989). The ﬁlters were hybridised with
equivalent amounts of cloned double-stranded cDNA labelled as
above. The intensities of the autoradiographic images were quanti-
ﬁed using IMAGE software (NIH, Bethesda, MD, USA).
Rapid ampliﬁcation of cDNA ends for cloning of full length
cDNA
Cloning of full length M41 cDNA was carried out by rapid ampli-
ﬁcation of cDNA ends (RACE) using a Marathon cDNA
ampliﬁcation Kit (Clontech) on 2 mg of poly(A)
+-containing
RNA derived from the MCF-7 cell line. The resulting adaptor-
ligated ds cDNA, which represented an uncloned ds cDNA library,
was used to perform 5' and 3' RACE reactions with the following
M41 gene speciﬁc primers for 5' and 3' RACE reactions
respectively: (5'-CCTCACGCTGTCTGGTTGGCTTTCC-3'), (5'-
GGTATGCAGCTGATAAGACGCTATAGAG-3'), based on the
isolated M41 EST sequence.
Human breast tissue, immunocytochemistry and in situ
hybridisation
Normal and benign human breast specimens and invasive ductal
carcinomas were obtained from the Liverpool Cancer Tissue Bank
Research Centre and the Royal Liverpool University Hospital
(Liverpool, UK) with legal consent as described previously (Taylor
et al, 1998). Immunocytochemical detection of oestrogen receptor
a (Platt-Higgins et al, 2000), in situ hybridisation and PCR reac-
tions (Liu et al, 2000) were carried out as described previously.
RESULTS
Construction of subtracted cDNA libraries
Libraries of cDNAs from the benign Huma 123 cells, suppression
subtracted with cDNA from MCF-7 cells (benign library), and
from the MCF-7 cells suppression subtracted with cDNA from
the Huma 123 cells (malignant library) were constructed. The
subtraction procedure reduced the abundancies of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) cDNA in the malignant
and benign subtracted libraries about 36-fold and 40-fold, respec-
tively, relative to their abundancies in the unsubtracted cDNAs,
as indictated by Southern hybridisation of PCR-ampliﬁed GAPDH
cDNA.
Overall, 87% of the randomly-picked cloned cDNAs yielded
sequence information. 128 sequences (comprising 72 different
known cDNAs, 53 expressed-sequence-tags (ESTs) and three
unmatched sequences) and 29 sequences (comprising 19 separate
known cDNAs, eight ESTs and two novel sequences) were obtained
from 174 and 52 sequenced cDNA clones from the malignant and
benign subtracted libraries, respectively.
Differential screening of the subtracted libraries using
reverse Northern hybridisation
The relative levels between the Huma 123 and MCF-7 cells of the
mRNAs corresponding to the sequenced cloned cDNAs, isolated
from the subtracted benign and malignant libraries, were estimated
by reverse Northern hybridisation, using as probes, cDNA produced
from mRNA from either the Huma 123 or MCF-7 cells. The hybri-
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mRNAs for 36B4 (Laborda, 1991) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), both of which show similar expression
between the Huma 123 and MCF-7 cell lines. Using an expression
ratio of over two-fold as cut-off, 22 of the 29 cDNA clones, and
99 of 119 cDNA clones examined by reverse Northern screening were
identiﬁed in the benign and malignant subtracted libraries, respec-
tively (Table 1). The identities of these cDNAs are shown in Table
2. The fact that these totals of cDNAs differentially-expressed by
more than two-fold represent respectively 76% and 83% of the total
cDNAs examined shows that the subtractive hybridisation procedure
was yielding predominantly differentially expressed cDNAs.
Four and 13 cDNAs were differentially expressed by over 15-fold
in the benign and malignant breast tumour cell lines, respectively
(Tables 1 and 2). Amongst the cDNAs expressed at a higher level
in the MCF-7 cells than in the Huma 123 cells were previously
characterised oestrogen-responsive genes, including pLIV-1
(Manning et al, 1988) (nine-fold), pS2 (Masiakowski et al, 1982)
(20-fold) and Cyclin D1 (Altucci et al, 1996) (15-fold), consistent
with the malignant breast cancer-derived MCF-7 cell line being
immunocytochemically positive, and the benign Huma 123 cell line
being immunocytochemically negative, for oestrogen receptor a
(not shown).
Clone M41
Clone M41, corresponded to an expressed sequence tag that repre-
sented an mRNA that was expressed at a 17-fold higher level in the
mRNA from the MCF-7 cells than in the Huma 123 cells (Table 2).
In Northern hybridisation experiments, the M41 probe hybridised
to a major band of RNA of 0.9–1.3 kb from the MCF-7 cells, but
there were two additional, but fainter bands of hybridisation at
1.8+0.1 kb and 3.8+0.1 kb (Figure 1). M41 mRNA was abun-
dantly expressed in RNA from oestrogen receptor-positive
mammary cell lines, T47-D, ZR-75, but was completely undetect-
able in oestrogen-receptor-negative cell lines, the malignant
human mammary cell line, MDA-MB-231 and the benign
mammary-derived cell lines Huma 123. M41 mRNA was also
undetectable in the normal-derived and benign human mammary
epithelial cell lines, Huma 7 and Huma 109 (Figure 1).
The sequence of M41 is located on the human genomic contig
GenBank NT_011512.3, which contains 28515322 bp of cloned
DNA from chromosome 21q22.3. Using RACE reactions to identify
5' and 3' regions of the M41 mRNA, 3' RACE yielded 10 separate
products, each of which corresponded to one of four patterns,
which precisely matched the NT_011512.3 genomic DNA sequence
to the poly(A)
+ addition sequence. 5'-RACE yielded 16 cloned
sequences, each of which corresponded to one of seven patterns,
which matched precisely the NT_011512.3 genomic DNA sequence.
Taken together these results identiﬁed at least seven experimen-
tally-determined alternatively-spliced transcripts of M41 mRNA
in the MCF-7 RNA (M41, A1-7, GenBank accession number-
s:AF401029, AF401030, AF401031, AF401032, AF401033,
AF401034, AF401035) containing up to three introns (Figure 2).
Genomic DNA in the region of M41 in contig NT_011512.3
contained two Alu repeat sequences, 264 bp and 286 bp in length
respectively, located between 27328305 and 27328568 and between
27329569 and 27329854, upstream and adjacent to two of the
proposed exons of the M41 gene. There are two oestrogen-
response-elements (ERE): AGGTCA-N23-TGACCT and AGGTCA-
N17-TGACC and one half ERE located between 27326764 and
27326797, 27328299 and 27328305, and between 27329636 and
27329663, of contig NT_011512.3 sequence (Figure 2), consistent
with the abundance of M41 mRNA in the ER positive cells lines
(Figure 1).
The gene for M41 does not presently occur in the annotated
human genome sequence. Thus, mapping of contig NT_011512.3
onto the published complete GenBank sequence of human chro-
mosome 21 placed the M41 sequence between nucleotides
40864055 bp and 40866330 bp, located between existing known
genes, PCP4 at 40348176 bp and BACE2 at 41649179 bp (Table
3) at a previously unmapped location. However, contig
NT_011512.3 also contains part of a previously described gene,
Down Syndrome Cell Adhesion Molecule (DS-CAM, cDNA acces-
sion AF023450; protein accession, AAC17967) on the
complementary strand in the region of the M41 gene. The M41
coding region is located on the complementary strand within the
323 kbp intron 2 of this gene (Figure 2).
In order to ﬁnd out whether M41 mRNA is expressed in human
tumour specimens, in situ hybridisation was carried out (Figure 3)
using sense and antisense probes derived from the region of the
M41 clone spanning two exons (Figure 2). Whereas there was no
hybridisation to any of the specimens with the sense probe, the
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Table 1 Summary of differentially-expressed clones between the benign
and malignant subtracted libraries using reverse Northern hybridisation
Number of cloned
cDNAs sequenced
Benign Malignant
subtracted subtracted
Level of differential expression library library
Highly differentially expressed clones (415-fold) 4 13
Signiﬁcant differentially expressed clones
(5–14.9-fold) 3 21
Differentially expressed clones (2.0–4.9-fold) 15 65
Hardly detectable or not differentially expressed
clones (52.0-fold) 7 20
Total number of differentially expressed cDNAs
identiﬁed 22 99
Total number of cloned cDNAs examined 29 119
A
B
M41
— 36B4
1        2       3         4        5       6      7        
Figure 1 Occurrence of M41 mRNA in human breast tumour cell lines.
Total RNAs were isolated from the SV40-immortalised normal human
mammary cell line, Huma 7 (lane 1), an elongated converted cell line,
Huma 109 (lane 2) derived from the benign mammary tumour-derived cell
line Huma 123 (lane 3), the malignant mammary epithelial cell lines MCF-7
(lane 4), T47-D (lane 5), ZR-75 (lane 6) and MDA-MB-231 (lane 7). These
RNAs were subjected to Northern hybridisation as described in Materials
and Methods, using a
32P-labelled probe to M41 mRNA (A) or to riboso-
mal phosphoprotein, 36B4, mRNA (B) to check for the loading of RNA
onto the gel. The arrows point to three bands of hybridisation in the three
oestrogen receptor positive human breast cancer cell lines.
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Table 2 cDNAs differentially expressed between benign and malignant human breast cell lines
cDNAs more highly expressed in the benign subtracted library
a
GenBank
Level of expression Name of cDNAs Accession No. Redundancy
b
Highly differentially expressed clones (Level ratios415-fold): S100A2; M87068
TGF-b induced gene product (BIGH3); M77349 16
RTP D87953 4
EST AA446686
Signiﬁcant differentially expressed clones (Level ratios between Human PAI-1 mRNA; X04744
5–14.9-fold): Human annexin VIII; M81844
KIAA 0205 D86960
Differentially expressed clones (Level ratios between 2.0–4.9): Human p cadherin; X63629
Human mRNA for ets-2; J04102
Human XIST; M97168 3
Human MMP1; Z48481
Human MEN1; AF001893 4
Novel sequence H113;
Prolylcarboxypeptidase; L13977
Vimentin 3; M25246
Serum amyloid A protein; X51445
Xq28 genomic DNA in the region of the L1CAM; U52112
Lysyl hydroxylase 2 U84573
4 ESTs AA234447
AA022923
AA249129
H56754
cDNAs more highly expressed in the malignant subtracted library
GenBank
Level of expression Name of cDNAs Accession No. Redundancy
b
Highly differentially expressed clones (ratio over 15-fold): Cyclin D1; X59798 4
Cleavage signal 1 protein; M61199 5
Cytokeratin 8; X74929 8
cAMP-dependent protein kinase type I-alpha subunit; M33336
EMP2; U52100 2
KIAA0107; D14663
M36/hAG2; AF038451 4
M41 EST; 4
M261 EST;
Orphan G protein-coupled receptor (RDC1); U67784 2
pS2; X52003 2
Soares testis cDNA clone 79584 EST; AA460587
U2 snRNP auxiliary factor M96982
Signiﬁcant differentially expressed clones (ratios between Beige-like protein (BGL); M83822
5–14.9-fold): Guanine nucleotide-binding protein G-s, alpha subunit; X04409
Death associated protein 5; X89713
Insulin induced protein 1 (INSIG1); U96876
KIAA0286; AB006624 2
LIV-1; U41060 3
Nuclear localization sequence receptor; U28386
Na-K-Cl cotransporter; U30246
Osteogenic protein; X51801
TATA-binding protein associated factor 30 kDa subunit; U13991 2
cDNA clone 257418; N39924
Soares pregnant uterus NbHPU EST; AA150356 2
Soares NhHMPu S1 H. cDNA clone 811880; AA456246
Soares NhHMPu S1 H. cDNA clone 68217; AA257072
EST100286; AA295139
cDNA clone 222365; H86418
H cDNA clone 562572; AA112140
cDNA clone 648604; AA223845
H105e3 gene; AF006487
M31;
M111
Differentially expressed clones (ratios between 2.0–4.9-fold): Soares foetal lung NbHL19W EST; W24624 2
B-myb gene; X13293 2
Small GTP-binding protein; L03303 3
CD24 signal transducer; L33930
Continued
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of 10 carcinoma specimens and three specimens were negative.
There was no statistically signiﬁcant correlation between M41 posi-
tivity and oestrogen receptor positivity for these samples (P=1.00,
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Table 2 (Continued)
cDNAs more highly expressed in the malignant subtracted library
GenBank
Level of expression Name of cDNAs Accession No. Redundancy
b
Mi-2 protein; X86691
GEN-418H06; D56188
endonuclease (FEN-1); L37374
U4/U6 small nuclear ribonucleoprotein hPrp4; AF016369
Zinc ﬁnger protein; U90919
cDNA clone 171742; H18393 2
Nuclear antigen H731; U83908 2
Bub3; AF053304
SWI/SNF complex 60 kDa subunit (BAF60a); U66617
p70 ribosomal S6 kinase alpha-I; M60724
RNA polymerase II elongation factor-like protein; Z47087 2
Apolipoprotein AI regulatory protein (ARP-1); M64497 2
HSP75; L15189 5
hsc70; Y00371
90 kDa heat-shock protein; X15183
Na+/H+ exchange regulatory co-factor; AF036241
Thymidylate synthase; X02308
Replication factor C; L07540
hBRAVO/Nr-CAM precursor; U55258
H(+)-ATPase subunit; S82464
ect2; L11316
Transferrin receptor; X01060
Cegp1; NM020052 2
Stanniocalcin precursor (STC); U25997
Teratocarcinoma protein phosphatase 2C alpha; S87759
Thioredoxin reductase; S79851
Tmp21-I; X97442
PAC 167A14 on chromosome 6q27; Z94721
KIAA0034; D21260 2
EST-cDNA clone 2279; T75244
Soares testis NHT H. cDNA clone 7282; AA39364
BAC clone RG363E19 from 7q31.1; AC004492
LIM-kinase1; U62293
cDNA clone IMAGE:1282957; AA744381
Soares foetal heart NbHH19W; AA709152 2
KIAA0069; D31885 2
BAC 15E1 EST; AL021546
cDNA clone 1377098; AA812811
EST43440; AA338506
cDNA clone 45061 5'; H08372
Soares foetal heart NbHH19W H. cDNA clone; AA056369
IMAGE:704185; AA279380
NbHPU H. cDNA clone 502819; AA137265
KIAA0228; D86981
EST; AB015752
Acyl-CoA synthetase II; D30666
26S protease subunit; X89718
DNA clone 234329; H93190
Semaphorin E; AB000220
Dihydrodiol dehydrogenase; M61937
Gamma-glutamylcysteine synthetase; M90656
Glucocerebrosidase; M19285
Collagen binding protein 2; D83174
Plasma gelsolin; X04412
Sortilin; X98248
Mannose 6-phosphate receptor; X56257
KIAA0587; AB011159
Cytokeratin 18; M26325
Human cosmid; AF002996
M102 EST;
M61 EST.
aA partial listing of cDNAs expressed at a higher level in the Huma 123 cells relative to the MCF-7 cells has been published previously (Liu et al, 2000).
bRedundancy is the
number of times the clone was picked from the library if greater than once.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(4), 423–431two-tailed Fisher Exact test). In contrast, there was no staining
using the antisense probe on a benign ﬁbroadenoma (Figure 3),
nor on four other ﬁbroadenoma specimens examined. There was
a statistically signiﬁcant difference between the benign and malig-
nant samples for M41 mRNA positivity (P=50.007, two-tailed
Fisher Exact test). Using a sensitive reverse transcript PCR (RT–
PCR) assay which yielded an M41-speciﬁc 147 bp product (Figure
4), RNA from 16 normal/benign, and 26 malignant breast tumour
specimens were screened for the presence of M41 mRNA (Table 4).
Although there was no correlation at all between the presence of
RT–PCR detectable M41 mRNA-speciﬁc PCR product and oestro-
gen receptor positivity (P=1.00, Fisher exact test) in the breast
carcinoma specimens, M1 mRNA was detectable in 15 out of 26
malignant lesions, but there was an ampliﬁed product in only
one out of ﬁve normal and one out of nine benign breast speci-
mens. There was a strong statistically-signiﬁcant difference
between the occurrence of M41 mRNA in carcinoma specimens
and its occurrence in normal/benign specimens (P=0.01, two-tailed
Fisher exact test) or benign specimens (P=0.028, two-tailed Fisher
exact test).
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50 kb
26958162
27326304
PRE  ERE
5' 3'
M41
Alu
1/2 ERE
3' 5'
DS-CAM
Alu
ERE
27792354
27330604
Rsa I
A
A
A
A
A
A
A
M41 (440 bp)
A1 (1282 bp)
A2 (1153 bp)
A3 (780 bp)
A4 (1267 bp)
A5 (1640 bp)
A6 (812 bp)
A7 (1185 bp)
300 bp
Figure 2 Alignment of the M41 gene and M41 transcripts. The gene region of chromosome 21q22.1 is shown at the top with the exons of the DS-CAM
gene shown as vertical bars. The location of the M41 gene is shown as a square to scale beneath the genomic DNA and expanded beneath. The location of
response elements for oestrogen (ERE) and progesterone (PRE) and Alu sequences are shown. The region of the original M41 cDNA isolated from the
MCF-7 subtracted library, and processing variants of M41 mRNA (A1–A7) obtained from the RACE reactions are shown as horizontal bars with gaps
indicating the intronic regions. Numbering refers to the base number of contig NT_011512.3. The 5' intron exon boundaries revealed by the RACE reac-
tions at 27328651, 27328698, 27328827, 27329381, and the 3' intron exon boundaries at 27328749, 27328894, 27329821 (enumeration of contig
NT_011512.3) all contained conserved GT / AG sequences and exhibited 62.5, 75, 87.5, 100, 75, 93.75, and 81.25% identity, respectively, to the consensus
sequences for 5' or 3' intron exon boundaries (Mount, 1982). The symbols (A) at the ends of the lines indicate the poly(A) addition sites. Variants contained
one of two alternative poly(A) addition sites (at 27330601 and 27330228 of NT_011512.3), with a consensus AATAAA poly(A)-addition signal, 29 and 19
nucleotides upstream of the poly(A)-addition sites, respectively. The lengths of the proposed mRNA variants arising from the 7 alternatively-spliced exons
correspond broadly to the sizes of two of the bands observed in the Northern blot for the mammary tumour cell line MCF-7 (Figure 1), strongly suggesting
that the RACE products are deﬁning near full length mRNAs. Horizontal arrows indicate the direction of transcription of the genes.
Table 3 Genes located on chromosome 21q22.3 in the region of the
M41 gene
Start Stop
a Symbol +/7
b Full name
c
39289926 39307551 ETS2 + v-ets avian erythroblastosis virus
E26 oncogene homologue 2
39659576 39667567 DSCR2 7 Down syndrome critical region gene 2
39680250 39683601 WDR9 7 WD repeat domain 9
39825341 39832075 HMG14 7 High-mobility group (nonhistone
chromosomal) protein 14
39861720 39879066 WRB + Tryptophan rich basic protein
39933270 40013964 SH3BGR + SH3 domain binding glutamic
acid-rich protein
40137952 40143513 B3GALT5 + UDP-Gal:GlcNAc b 1,3-galacto-syl-
transferase, polypeptide 5
40348176 40410103 PCP4 + Purkinje cell protein 4
40864053 40866326 M41 + Identiﬁed in this paper
41649179 41756844 BACE2 + b-site APP-cleaving enzyme 2
41660175 41662034 LOC82404 + Hypothetical gene supported by
NM_002581
41843016 41889940 MX2 + Myxovirus (inﬂuenza) resistance 2,
homolog of murine
41907238 41940262 MX1 + Myxovirus (inﬂuenza) resistance 1,
homolog of murine (interferon-
inducible protein p78)
aLocation on chromosome 21 sequence.
b+o r7 strand of the DNA.
cBold denotes
M41 gene isolated in the MCF-7 subtracted library.
Table 4 M41 mRNA in breast tumour specimens
Total M41 M41
number mRNA mRNA
Breast tumour specimens tested positive negative % positive
Normal breast specimens 6 1 5 17
Benign lesions 10 1 9 10
a
Carcinomas 26 15 11 58
b
aNot statistically signiﬁcantly different from nromal (P=1; Fisher exact test).
bStatisti-
P=0.028; Fisher exact test) and benign lesions and normal (P=0.01; Fisher exact test).
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Subtracted libraries have been constructed from well-characterised
benign and malignant human breast tumour cell lines. The Huma
123, typical of human benign tumour cells, is oestrogen receptor
negative and was compared with the less-malignant oestrogen
receptor positive MCF-7 cell line, in preference to a more-malig-
nant oestrogen receptor negative one such as MDA-MB-231,
which lacks epithelial markers characteristic of breast carcinoma
cells (Engel and Young, 1978). Although it was expected that
oestrogen responsive cDNAs would be present in an MCF-7
library, the use of the better-deﬁned breast epithelial MCF-7 cells
reduced the likelihood of isolating cell-culture-related cDNAs.
The libraries were discrete, and subtracted cloned cDNAs were
differentially expressed when tested by reverse Northern and
Northern hybridisation techniques. Although some cDNAs were
differentially expressed by up to 36-fold, 76% and 83% of cDNAs
in the benign and malignant libraries, respectively, were differen-
tially expressed at a level of greater than two-fold. In both
libraries, the majority of cloned cDNAs (66% and 56% for the
benign and malignant subtracted libraries, respectively) represented
products of previously-described genes. However, 28% of the
sequenced clones in the benign cell library represented ESTs, but
for the malignant library this proportion was somewhat higher at
41%, perhaps reﬂecting a greater number of previously-uncharac-
terised genes differentially-expressed in the malignant cells
relative to the more tightly regulated cells of benign tumour origin.
Only small proportions of the libraries were picked for sequencing.
The observation that in each library, the majority of randomly
picked cloned cDNAs were both differentially expressed and unique
sequences suggests that these large libraries represent resources
which contain further differentially-expressed cDNAs.
A recent study, using MCF-7 cells grown in the presence or
absence of steroids as the starting material for subtraction, yielded
14 oestrogen responsive cDNAs (Ghosh et al, 2000). In another,
the dissimilar oestrogen-receptor positive MCF-7 cell line and the
oestrogen receptor negative, breast carcinoma cell line MDA-MB-
231 yielded only 28 separate cDNAs (Kuang et al, 1998). In the
present experiments, over 100 cDNAs have been isolated so far,
possibly suggesting greater variation in gene expression between a
benign and a malignant mammary cell line, than between two
malignant mammary cell lines (Kuang et al, 1998). However, a
small subset of cloned cDNAs found to be elevated in the present
malignant library was also differentially-expressed in the
previously-reported screen between the MCF-7 cells and MDA-
MB-231 cells (Kuang et al, 1998), including cytokeratins 8 and
18 and CD 24 (Yang et al, 1999). Since the Huma 123 cell line
and the MCF-7 cell lines used in the present study have the same
oestrogen receptor status as the MDA-MB-231 cells and the MCF-7
respectively (Kuang et al, 1998), it is likely that the mRNAs repre-
sented by these cloned cDNAs, are associated with the differing
oestrogen receptor status of the presently-used cell lines. Further-
more, other ER-dependent mRNAs, including Cyclin D1 (Altucci
et al, 1996), pS2 (Masiakowski et al, 1982) and pLIV-1 (Manning
et al, 1988), were also present in the malignant subtracted library.
cDNAs from the present libraries that have been described
previously suggest that the libraries do contain cDNAs with rele-
vance in the development of breast cancer. For example, over-
expression of Cyclin D1 has been shown to distinguish breast carci-
nomas and in situ breast lesions from benign lesions (Weinstat-
Saslow et al, 1995). Amongst other cDNAs up-regulated in the
malignant cell library, were those corresponding to mRNAs for a
putative G-protein-coupled receptor (Libert et al, 1989), for
proteins associated with the mitotic spindle checkpoint, BUB3
(Brady and Hardwick, 2000) and with chromatin remodelling
(Wang et al, 1996; Zhang et al, 1998; Vignali et al, 2000). Two
cDNAs (LIM kinase and BUB3), which are differentially-expressed
in the present malignant library, have also been found to be differ-
entially expressed in a subtracted library representing cDNAs
expressed in a pathologically homogeneous breast carcinoma speci-
men subtracted with cDNA from 50000 ductal-carcinoma-in-situ
cells microdissected from the surrounding normal tissue (Liu,
2001). Although the dependence of expression of the mRNAs for
these cloned cDNAs on oestrogen is not known, the present work
clearly identiﬁes many relevant cloned cDNA targets for further
investigation.
The subtracted library of cDNAs down-regulated in the MCF-7
cells relative to the Huma 123 cells contained a cDNA correspond-
ing to the mRNA for an EF-hand protein, S100A2, which was
shown previously to be abundantly expressed in both normal breast
and benign breast tumour specimens (Liu et al, 2000), but only
detectable in less than 15% of malignant breast cancer specimens
tested. This result suggests that the suppression subtractive hybridi-
sation produces libraries containing cDNAs differentially expressed
between benign and malignant cells.
The library of cDNAs up-regulated in MCF-7 cells relative to the
benign Huma 123 cells contained ESTs that exhibited oestrogen
dependence. One such cloned cDNA, M41, corresponds to a tran-
script of a previously unmapped gene located on chromosome
21q22.3. 5' and 3' RACE experiments showed that M41 mRNA
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Figure 3 In situ hybridisation of M41 mRNA in human breast tumours.
Histological sections of breast carcinoma specimens (A–G), and of one
benign tumour specimen (H) were subjected to in situ hybridisation using
antisense (A, C, E, G, H) or sense (B, D, F) probes to M41 mRNA as
described in Materials and Methods. The carcinoma cells in the specimens
in A, C, E and G stain with an antisense probe of M41 cRNA, whereas
there was no staining of adjacent sections of the specimens with sense
M41 RNA probe (B, D, F). (H) shows an example of a ﬁbroadenoma
which did not stain with an antisense probe, in common with four other
ﬁbroadenomas tested. Magniﬁcation is 6231 (A–D, F)o r6578 (E,
G, H). Bars=43 mm( A–D, F)o r1 7mm( E, G, H).
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some of which contain short open-reading-frames which can be
translated into protein using a coupled in vitro transcription trans-
lation system (not shown). However, the splice variants were not
sufﬁciently different in size to be individually distinguishable in
the Northern blotting experiments. The individual introns and
exons of this new gene have now been precisely mapped onto chro-
mosome 21 contigs.
M41 mRNA was shown to be produced by the carcinoma cells
of breast cancer specimens using in situ hybridisation, and, using
a PCR assay, M41 mRNA was found not to be statistically signiﬁ-
cantly correlated with the presence of oestrogen receptor, nor with
the immunocytochemical detection of the oestrogen-responsive
progesterone receptor (not shown) in a panel of carcinoma speci-
mens. Thus, although M41 mRNA relates to oestrogen receptor
status in the malignant breast-derived cell lines tested, in the carci-
noma specimens, the relationship is stronger between benign and
malignant than between oestrogen receptor positive and negative.
These results probably relate to the complexity of oestrogen recep-
tor regulation of gene expression. It is the results with the
carcinoma specimens that are likely to be more important. A simi-
lar weakening of correlation with ER status of carcinoma
specimens has been found for two different cDNAs, pDZK1 and
GREB1, which also showed a strong correlation with ER in cell
lines (Ghosh et al, 2000), but which exhibited a much weaker
correlation with oestrogen receptor positivity in carcinoma speci-
mens. This lack of correlation between oestrogen responsive
cDNAs in MCF-7 cells and carcinoma specimens, and the variabil-
ity of patterns of gene expression in breast carcinomas has recently
also been reported using array technology (Gruvberger et al, 2001).
The M41 gene contains an oestrogen response element associated
with an intronic alu repeat sequence. Such variant alu-DNA
repeats, that can act as oestrogen and other steroid hormone
response elements, have been described previously (Norris et al,
1995; Babich et al, 1999). The M41 gene alu-associated ERE is of
the inverted repeat type with a 17 nucleotide separation (IR-17)
as described by Babich et al (1999). Whilst it is known that similar
elements can activate reporter gene activity in a hormone depen-
dent manner in cultured cells (Norris et al, 1995; Babich et al,
1999) and also bind proteins in vitro from nuclear extracts of
cultured cells (Babich et al, 1999), little is known of their activity
in carcinoma cells that have not been subjected to cell culture.
In the present experiments on carcinoma specimens, the statisti-
cally-signiﬁcant difference in the expression of M41 mRNA
between malignant human breast specimens and either benign or
benign and normal breast specimens, but the lack of correlation
with oestrogen receptor status, suggests that M41 mRNA is up-
regulated during the malignant progression of carcinomas, by an
oestrogen-independent mechanism.
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A
B
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M         1         2       3         4        5         6       7
— 147 bp
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0.1 —
M     1     2      3     4      5      6     7      8      9     10    11    12    13    14    15    16    17
— 147 bp
Sample  MCF-7 IDC IDC IDC  IDC  IDC IDC  IDC IDC   N     B     IDC  IDC    –     –       B     N
ER                +     +      –      +      +      –     +      +     +    N/A  N/A     +      +                   N/A  N/A
Figure 4 Occurrence of M41 mRNA in benign and malignant human mammary cell lines and breast tumour specimens by RT–PCR. Total RNA from
human mammary cell lines. Normal breast derived Huma 7 (A, lane 1), benign breast derived Huma 123 (lane 2), Huma 109 (A, lane 3), and breast carci-
noma-derived cell lines, MCF-7 (A, lane 4), T47-D (A, lane 5), ZR-75 (A, lane 6), MDA-MB-231 (A, lane 7), and total RNA from breast carcinoma speci-
mens (B, lanes 2–9, 12–13), normal breast specimens (B, lanes 10 and 17), and benign breast specimens (B, lanes 11 and 16) were ampliﬁed by RT–PCR
using primers speciﬁc for M41 yielding PCR products of 147 bp. (B), lanes 14 and 15 are the negative RT–PCR controls, and lane 1 is MCF-7 cell line RNA
as positive control. The resulting RT–PCR products were subjected to agarose gel electrophoresis and stained with ethidium bromide, as described in
Materials and Methods. Lane M, DNA molecular weight markers. The estrogen receptor status of the specimens is shown beneath panel B as +, positive
or -, negative. N/A is not available. The faint bands in A, lanes 1–3 and 7 arise from the ampliﬁcation of a low, otherwise undetectable, level of M41 mRNA
in these specimens. The diffuse bands in B, lanes 2, and 10–17 at 5100 bp are caused by primer dimers. DNA sequencing of the 147 bp band conﬁrmed
its identity with the expected sequence of the ampliﬁed band.
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